HUTCHMED (China) Ltd (HCM): what the price assumes

Generated: 2026-07-25 · Source: https://boothcheck.com/report/HCM

Headline

Field	Value
Ticker	HCM
Company	HUTCHMED (China) Ltd
Current price	$11.00/sh
Composition	Invoiced Goods - Marketed Products 18% / Invoiced Goods - Distribution 48% / Services - Commercialization of Marketed Products 8% / License & Collaborations - Services 5% / License & Collaborations - Royalties 12% / License & Collaborations - Licensing 2% / License & Collaborations - Manufacturing supply 6%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	revenue-multiple
EV / sales paid	3.6x
Steady-state operating margin assumed	15.5%
Must persist for	5.3y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 10% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.7 years.

How unusual the bet is: within-range

Reference	Value
vs own history	+0.42σ
sustained it ~5.3 years at this level	35%
implied end-window share	0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	0.32x	4	justifies
Earnings	0.26x	2	justifies
Relative	0.29x	4	justifies
Growth	0.90x	1	justifies

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=11)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$0.00	—	no	Negative/zero FCF — equity value floored at $0
DCF Exit Multiple	Growth	$0.00	—	no	Negative/zero FCF or EBITDA — equity value floored at $0
Relative Valuation	Relative	$50.33	0.22x	yes	P/E 16.08x (blended: static sector reference 24x + trailing (TTM) 4x), scenarios: 13.1x / 16.1x / 19.1x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$28.29	0.39x	yes	BV/sh $7.09, ROE (TTM) 36.9%, ke 9.3%
Two-Stage Excess Return	Asset	$61.25	0.18x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$12.26	0.90x	yes	Rev $0.5B, growth 20% (input: historical growth; tapered), Terminal P/S: 2.8x / 3.5x / 4.2x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$31.20	0.35x	yes	EPS $2.60, growth 2% (input: historical EPS growth), PEG=2.10 (Overvalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	—	—	no	—
Residual Income	Asset	$44.38	0.25x	yes	BV $7.09 + 5yr PV of (ROE (TTM) 36.9% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham Number	Asset	$20.37	0.54x	yes	√(22.5 × EPS $2.60 × BVPS $7.09) — Graham's conservative floor
EV/EBITDA Relative	Relative	—	—	no	—
FCF Yield	Earnings	—	—	no	—
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	$83.89	0.13x	yes	EPS $2.60 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	—	—	no	—
P/Sales Sector	Relative	$12.57	0.88x	yes	Revenue $0.55B × sector P/S 4.0x
PEG Fair Value	Relative	$97.50	0.11x	yes	EPS $2.60 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings Yield	Earnings	$28.11	0.39x	yes	EPS $2.60 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$1.2b
Interest coverage	-13.7x
Share count CAGR (dilution)	2.4%
Burning cash	yes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

• HUTCHMED's lead drug fruquintinib, sold outside China by Takeda as Fruzaqla, grew in-market sales 26% to $366.2 million in 2025, the proof point that a China-discovered oncology drug can scale in Western markets.
• The price already assumes a long, profitable future: at roughly 14 times revenue it embeds a swing from today's operating loss to a mid-teens operating margin sustained for well over a decade, a persistence only about one in seven comparable fast-growers has achieved.
• Watch the savolitinib global Phase III readout, which if positive could support worldwide filings, and the 2026 oncology and immunology revenue guidance of $330 million to $450 million.

Bull Case

Valuing a company like HUTCHMED is a different exercise than valuing a steady-state business, and the bull case lives in that difference. Standard cash-flow models systematically undervalue a drug portfolio with binary clinical outcomes, because they discount a pipeline as if each program were a coin flip on a spreadsheet rather than a series of approvals that, once they land, throw off royalties for years. HUTCHMED is past the riskiest part of that curve on its lead asset: fruquintinib is approved and selling, and its ex-China partner Takeda grew Fruzaqla in-market sales 26% to $366.2 million in 2025. That is the validation that matters most for a China biopharma, a domestically discovered oncology drug succeeding commercially in Western markets through a major global partner.

The partnership model is the structural advantage. HUTCHMED books revenue across Eli Lilly for Elunate, Takeda for Fruzaqla, and AstraZeneca for Orpathys, plus its own China commercial operation. Each of those partners carries the heavy lifting of Western commercialization and regulatory work while HUTCHMED keeps the discovery engine and the royalty stream. That structure lets a mid-cap company punch at global scale without funding a global sales force, and it is why the license-and-collaboration lines now make up a meaningful slice of the revenue mix.

The pipeline is where the optionality compounds. The FRUSICA-2 Phase III in renal cell carcinoma read out strongly, with fruquintinib plus sintilimab reaching a median progression-free survival of 22.2 months against 6.9 months for the comparator, a result that opens a new indication. Savolitinib has completed enrollment in a global Phase III that, if positive, could support worldwide filings, adding a second drug to the ex-China franchise. Sitting on more than $1.2 billion of net cash, HUTCHMED can fund those readouts without tapping the market, and management guided 2026 oncology and immunology revenue to $330 million to $450 million. The bull case is a de-risked lead asset, a partner-funded global model, and a cash-rich balance sheet financing the next two drugs.

Bear Case

The valuation methods do not agree on HUTCHMED, and the disagreement is the heart of the bear case. The company runs a trailing operating loss, with an operating margin around negative 19%, so there is no current profit to value. That forces the price to be read against sales, and at roughly 14 times revenue it is an aggressive multiple by any conservative measure. The relative and asset-based methods, which try to anchor on book value or a sector earnings multiple, scatter widely because a loss-making company breaks their assumptions; only the methods that credit a long runway of future growth reach the price. When the only methods that justify a price are the ones that assume the future works out, the conservative methods are usually the more honest read, and here they say the price is well ahead of the demonstrated fundamentals.

The arithmetic of what the price requires makes the stretch concrete. At today's level the price implies HUTCHMED swings from its current operating loss to an operating margin around 15.5% and sustains revenue growth near its self-funding ceiling for roughly 17 years. That is not a near-term bet; the near-term growth pace is within what the company has shown. The bet is on how long it must persist, and history is unkind to that duration: only about 14% of comparable fast-growers sustained that pace for even a decade. A single clinical setback, a slower-than-hoped Fruzaqla ramp, or a savolitinib Phase III miss would remove a leg of the multi-year story the price depends on.

Layered on top is a risk the income statement cannot capture: jurisdiction. HUTCHMED is a China-based biopharma whose value increasingly rests on selling drugs in the United States and Europe through Western partners. Geopolitical friction, drug-pricing policy, and the regulatory treatment of China-originated assets are all external variables with real leverage on the thesis, and none of them is reflected in a revenue multiple. The company is also still burning cash at the operating line; the large cash pile buys years of runway, but a business that has not yet demonstrated sustained profitability is asking investors to underwrite both the science and the geopolitics for the better part of two decades.

Valuation

HUTCHMED runs a trailing operating loss, so there is no current profit to capitalize and the price has to be read against revenue. At about $10.27 (June 27, 2026) the stock trades near 14 times sales, which inverts into a demanding assumption: the business eventually reaches an operating margin around 15.5% and grows revenue near its self-funding ceiling for roughly 17 years. The near-term growth rate is within what the company has recently delivered; the stretch is entirely in the duration. Only about one in seven comparable fast-growers sustained that pace for even ten years, which is why the priced-in assumption reads as elevated rather than comfortably supported.

The methods split along the line that always separates a profitable company from a development-stage one. The approaches that credit future growth reach the price; the asset-value and earnings-based approaches scatter, because a company without steady profit gives them no stable anchor. The sector earnings multiple, near 24 times for profitable peers, is not directly applicable to a business still running a loss. The honest framing is that the price is a forward bet on a drug portfolio, not a value supported by trailing fundamentals, and the spread between the optimistic and conservative methods is the size of that bet.

The balance sheet is the clearest fact and the strongest part of the case. HUTCHMED holds more than $1.2 billion of net cash against minimal debt, so the company can fund its clinical readouts and commercial expansion for years without dilution, and the share count has grown only modestly. That cash is the floor under the downside: even if the multi-year growth story slips, the business is not at financial risk in the near term. What a buyer underwrites at this price is the durability of the oncology franchise across a horizon measured in many years, with the cash balance ensuring the company survives long enough to find out whether the science and the partnerships deliver.

Catalysts

HUTCHMED's 2025 full-year results, reported in March 2026, centered on the global commercial ramp of fruquintinib. Sold outside China by Takeda as Fruzaqla, in-market sales rose 26% to $366.2 million from $290.6 million in 2024, the company's most important proof of Western commercial traction. In-market sales also include products marketed by Eli Lilly (Elunate) and AstraZeneca (Orpathys) alongside HUTCHMED's own China operations.

The clinical catalysts are where the forward value sits. At ESMO 2025, the FRUSICA-2 Phase III in second-line renal cell carcinoma showed fruquintinib plus sintilimab reaching a median progression-free survival of 22.2 months versus 6.9 months for the comparator, with an objective response rate of 60.5% against 24.3%, opening a path to a new indication. Savolitinib has completed enrollment in a global Phase III trial that, if positive, could support worldwide regulatory filings.

For 2026, management guided oncology and immunology consolidated revenue to a range of $330 million to $450 million, reflecting continued China commercial growth, the ongoing global expansion of Fruzaqla, and potential new partnerships. The savolitinib readout and the pace of the Fruzaqla ramp are the developments most likely to move the fundamental story over the next several quarters.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• LEGN (Legend Biotech Corp)
• (no filing in the citation store)
• EXEL (EXELIXIS, INC.)
• (no filing in the citation store)
• IMCR (Immunocore Holdings plc)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

HUTCHMED 2025 full-year results, March 2026 · HUTCHMED FRUSICA-2 results, ESMO 2025